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INTRODUCTION
Carbamazepine (CBZ) was first synthesized by Walter Schindler 
in 1953. In 1962, Blom saw its potential in the treatment of tri-
geminal neuralgia.1 Since the U.S. Food and Drug Administra-
tion (FDA) approved CBZ tablets for epilepsy and trigeminal 
neuralgia more than 50 years ago, CBZ has become a first 
drug of choice to treat seizure disorders and neuropathic pain. 
It is also used as a second-line treatment for bipolar disor-
der.2,3 CBZ is predominantly metabolized in the liver. At least 
30 different metabolites have been identified, including car-
bamazepine-10,11-epoxide.4 The metabolites of CBZ not only 
contribute to anti-convulsant and anti-neuralgic properties, 
but can also cause adverse reactions. The various types of ad-
verse drug reactions (ADRs) of CBZ were first reported not 
long after approval of the drug:5 a fair amount of severe skin 
reactions to CBZ, as well as mild ADRs, have been reported.6
Oxcarbazepine (OXC), the keto-analogue of CBZ, has been 
developed to help prevent side effects stemming from the me-
tabolites of CBZ. The drug is primarily metabolized into 10-hy-
droxy-10,11-dihydrocarbamazepine, a therapeutically active 
metabolite.7 Compared to CBZ, in a randomized double-blind 
crossover trial, the use of OXC achieved a reduction in the total 
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number of seizures, increased alertness and concentration, and 
disappearance of allergic skin reactions associated with CBZ.8 
OXC is known to exhibit anti-epileptic activity comparable with 
CBZ when a 50% higher dose is applied. Despite the higher dose, 
the incidence and severity of adverse reactions are reportedly 
lower than those with CBZ.9
CBZ and OXC can cause similar adverse reactions, such as 
skin rash, central nervous system disorders, and digestive sys-
tem disorders. They are also known to be causative drugs for se-
vere cutaneous adverse reactions (SCARs), such as erythema 
multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epi-
dermal necrolysis (TEN), and drug reaction with eosinophilia 
and systemic symptoms (DRESS).6,10 Based on the individual 
case safety reports of SCARs in the Korean population from 1988 
to 2013, CBZ is known to be the second most common causative 
drug for SCARs, including SJS, TEN, and DRESS.11
This study aimed to examine the frequency and clinical fea-
tures of ADR caused by CBZ and OXC using the spontaneous 
ADR reporting database of Yonsei University Severance Hos-
pital & Dental Hospital.
MATERIALS AND METHODS
Using the pharmacovigilance database and spontaneous ADR 
reporting data of Yonsei University Severance Hospital & Den-
tal Hospital (Seoul, Korea) from January 1, 2010 to January 31, 
2020, we selected the data and reports of patients with sponta-
neous reports of ADR associated with CBZ and OXC. The sub-
jects were of ages 15 and over, and their diagnoses were classi-
fied. The clinical features of ADR reports were classified using 
the preferred terms of System Organ Class published by Med-
DRA®, Medical Dictionary for Drug Regulatory Activities, a stan-
dardized dictionary of medical terminology, developed under 
the auspices of the International Conference of Harmonisation 
(MedDRA MSSO, Brussels, Belgium): “Skin disorders,” “Ner-
vous system disorders,” “Gastrointestinal disorders,” “Blood and 
lymphatic system disorders,” “General disorders and adminis-
tration site conditions,” and “Hepatobiliary disorders.”
Symptoms of skin disorders included rash, urticaria, erythe-
ma, and symptoms of fatal cutaneous reaction (e.g., EM, SJS, TEN, 
and DRESS). Symptoms of nervous system disorders included 
sleepiness, dizziness, memory impairment, headache, and trem-
or. Indigestion and vomiting were classified as gastrointestinal 
disorders. General disorders showed fever and weakness.
With the obtained data and reports, we analyzed the ADR in-
cidences for each drug in connection with the reported daily 
dose. For CBZ, we also compared the stated ADR daily dose of 
immediate-release (IR) and controlled-release (CR) formulations.
This study protocol was approved by the Institutional Review 




From obtained reports, we calculated incidences according to 
the clinical features of ADRs for CBZ and OXC. The data were 
analyzed using Statistical Software for Social Sciences version 
25 (IBM Corp., Armonk, NY, USA). Descriptive statistics and 
chi-square tests were used. Statistical significance was consid-
ered at p<0.1.
RESULTS
There were 9312 patients who have been prescribed either CBZ 
or OXC among a total of 10419 cases, of which 5094 (48.9%) were 
male and 5325 (51.1%) were female; the remaining 1107 were 
prescribed both. The age of the subjects ranged from 15 to 97, 
with a mean age of 46.6 years. The diagnoses of the patients were 
classified as “neuropathic pain,” “episodic neurologic symptoms,” 
“bipolar disorders,” or others (Table 1).
The spontaneous ADR reporting system contained records 
of 204 ADR cases in 195 patients. There were 107 patients who 
experienced ADRs for CBZ only, 79 patients for OXC only, and 
nine for patients taking both drugs. 153 patients (75.0%) were 
reported to have one ADR clinical feature, while 39 patients 
(19.1%) and 11 patients (5.4%) had two and three ADR clinical 
features, respectively. Only 1 patient (0.5%) presented with four 
ADR clinical features. There was no statistically significant dif-
ference in ADR incidence for CBZ and OXC (CBZ: 1.8%, OXC: 
2.2%, p=0.169). ADR incidence did not correlate with age (p= 
0.495). Female, however, showed higher ADR rates for both 
drugs (p<0.001) (Table 2). 
The most common types of ADRs associated with the drugs 
Table 1. Baseline Characteristics of the Patients
CBZ OXC Total
Sex
Male 3040 (29.2) 2054 (19.7) 5094 (48.9)
Female 3368 (32.3) 1957 (18.8) 5325 (51.1)
Age (yr)
15–19 280 (2.7) 630 (6.0) 910 (8.7)
20–29 873 (8.4) 645 (6.2) 1518 (14.6)
30–39 966 (9.3) 634 (6.1) 1600 (15.4)
40–49 1030 (9.9) 642 (6.2) 1672 (16.0)
50–59 1180 (11.3) 612 (5.9) 1792 (17.2)
60–69 1038 (10.0) 506 (4.9) 1544 (14.8)
70 and over 1041 (10.0) 342 (3.3) 1383 (13.3)
Diagnosis
Neuropathic pain 2582 (24.8) 886 (8.5) 3468 (33.3)
Episodic neurologic symptoms 2959 (28.4) 2964 (28.5) 5923 (56.8)
Bipolar disorders 410 (3.9) 44 (0.4) 454 (4.4)
Others 457 (4.4) 117 (1.1) 574 (5.5)
Total 6408 (61.5) 4011 (38.5) 10419 (100)
CBZ, carbamazepine; OXC, oxcarbazepine.
Data are presented as n (%).
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were mild skin disorders (non-SCAR), followed by nervous sys-
tem disorders (Table 3). CBZ caused more ADRs related to the 
nervous system (p=0.087) and general (p=0.077) and hepato-
biliary (p=0.091) disorders than did OXC (Fig. 1A). OXC was as-
sociated with a higher incidence of mild skin disorders (p=0.013) 
(Fig. 1B). Six patients reported SCARs, including EM, SJS, TEN, 
and DRESS, by CBZ. The symptoms started with skin rash and 
urticaria 14–30 days after taking the drug. Five of them had dis-
continued the drug right after the symptoms appeared. They 
were referred to the Departments of Allergy and Immunology 
and of Dermatology and Infectious Diseases and diagnosed with 
EM (F/70), SJS (F/74, F/37, F/67), TEN (F/44), and DRESS (M/74). 
After supportive care, all six experienced relief of symptoms. 
There were no reports of SCARs due to OXC. 
The daily doses of the drugs, compared to the initial daily dose 
in patients without ADRs, were analyzed. At daily doses lower 
than the recommended initial dose (400 mg/day for CBZ IR and 
CR formulation, 600 mg/day for OXC), all drugs were found to 
cause ADRs (Fig. 2).
DISCUSSION
OXC is indicated in both monotherapy and adjunctive therapy 
for the treatment of partial seizures with or without secondary 
generalization in adults and children above 4 years (USA) or 6 
years (Europe) of age. However, in this study, we chose subjects 
older than 15 years, since CBZ is more rapidly metabolized to 
carbamazepine-10,11-epoxide in children below age 15.12 Thus, 
over the age of 15 years, the result of our study showed no sig-
nificant relationship between age and ADR incidence.
Gender differences in ADRs have been reported mainly for 
gastrointestinal disorders.13 In males, electrolyte disturbances 
are known to be more frequent,14 while female commonly pres-
ent with more gastrointestinal and cutaneous allergic reactions. 
Female generally have a lower lean body mass, reduced hepatic 
clearance, and lower activity of cytochrome P450 (CYP) en-
zymes; thereby, female tend to metabolize drugs at lower rates 
than male.15 Female also show higher rates of consultation and 
complaints, as well as better compliance with drugs.16
Our results revealed no significant differences in overall ADR 
incidences between CBZ and OXC. However, nervous system 
disorders, general disorders, and hepatobiliary disorders oc-
curred mostly with CBZ. Since OXC was developed by altering 
the structure of CBZ with the intent to avoid metabolites caus-
ing side effects, the mechanism of action of OXC mainly involves 
blockade of sodium channels, but differs from CBZ by modu-
lating different types of calcium channels. In contrast to CBZ, 
which is oxidized by the cytochrome P-450 system, OXC under-
goes reductive metabolism at its keto moiety to form the mono-
hydroxy derivative, which is glucuronidated and excreted in 
the urine. The involvement of the hepatic cytochrome P-450-de-
pendent enzymes in the metabolism of OXC is minimal.17
The fact that there was no report of SCAR directly for OXC, 
while CBZ had six cases, is notable. Fortunately, all patients 
with SCARs to CBZ received treatment after proper specialist 


















CBZ 59 (0.92) 6 (0.09) 42 (0.66) 11 (0.17) 10 (0.16) 14 (0.22) 8 (0.12) 17 (0.27) 6408 (100)
OXC 58 (1.45) 0 (0.00) 16 (0.40) 6 (0.15) 9 (0.22) 3 (0.07) 1 (0.02) 8 (0.20) 4011 (100)
p value 0.013 0.053 0.087 0.785 0.427 0.077 0.091 0.503
Total 117 (1.12) 6 (0.06) 58 (0.56) 17 (0.16) 19 (0.18) 16 (0.15) 9 (0.09) 25 (0.24) 10419 (100)
ADR, adverse drug reaction; SCAR, severe cutaneous adverse drug reaction; CBZ, carbamazepine; OXC, oxcarbazepine.
Data are presented as n (%).
*Severe skin disorders include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reactions with eosinophilia and systemic 
symptoms.





CBZ 116 (1.8) 6292 (98.2) 6408 (100)
OXC 88 (2.2) 3923 (97.8) 4011 (100)
Age (yr) 0.495
15–19 13 (1.4) 897 (98.6) 910 (100)
20–29 37 (2.4) 1481 (97.6) 1518 (100)
30–39 26 (1.6) 1574 (98.4) 1600 (100)
40–49 35 (2.1) 1637 (97.9) 1672 (100)
50–59 34 (1.9) 1758 (98.1) 1792 (100)
60–69 35 (2.3) 1509 (97.7) 1544 (100)
70 and over 24 (1.7) 1359 (98.3) 1383 (100)
Sex <0.001
Male 63 (1.2) 5030 (98.8) 5093 (100)
Female 141 (2.6) 5185 (97.4) 5326 (100)
Total 204 (2.0) 10215 (98.0) 10419 (100)
ADR, adverse drug reaction; CBZ, carbamazepine; OXC, oxcarbazepine.
Data are presented as n (%).
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referral. Management should begin with the withdrawal of the 
suspected drug, as early withdrawal of drugs with a short elim-
ination half- life is associated with better outcomes of patients 
with severe drug eruptions. In the one case of the SJS patient, 
changing the drug right after the occurrence of the severe ADR 
did not eradicate the symptoms. In cases of acute skin failure, 
patient management must be undertaken in specialized inten-
sive care units or in burn units.18 The prompt decision of the cli-
nician is necessary for a favorable prognosis.
According to the ADR reports in this study, there was a differ-
ence in daily doses between IR and CR tablets of CBZ in relation 
to ADRs. For CBZ CR, most of the ADR cases were reported at 
400 mg/day, while CBZ IR had a number of reports at 100, 200, 
and 300 mg/day. OXC mainly showed ADRs at a dose of 150, 300, 
and 600 mg/day. This might arise as a result of use instructions 
provided to patients at Yonsei University Severance Hospital 
& Dental Hospital. The CBZ medications we use consist of 200 
mg tablets of CBZ CR formulation and 200 mg and 400 mg tab-
lets of CBZ IR formulation. For OXC, 300 mg and 600 mg OXC 
IR formulations are available. The recommended initial doses 
of CBZ and OXC are 200 mg twice daily (400 mg/day) and 300 
mg twice daily (600 mg/day), respectively. Although the accura-
cy of tablet splitting is controversial,19-21 IR formulation can be 
halved, while CR formulation is not recommended to be mod-
ified. Since the halved CBZ IR and OXC already showed a con-
siderable number of ADR reports, we recommend starting from 
a lower dose to prevent possible ADR events. Also, clinicians 
should consider administering half-dose tablets of CBZ and 
OXC.
This study was based on spontaneous reports of clinicians 
prescribing the drugs. All spontaneous reporting systems are 
affected by under-reporting.22 Considering the purpose of the 
system, most reports were intended to document that the doc-
tor had to change or withdraw the medication due to ADR symp-
toms. We should keep in mind that the incidence might not 
include mild symptoms that the patient could endure during 
treatment.
As CBZ and OXC are commonly used in clinics, clinicians 
should be aware of the likelihood of ADRs with respect to these 
drugs. Although OXC had more reports of mild skin reactions, 
SCARs only occurred with CBZ. Furthermore, other types of 
ADRs, such as nervous system disorders, general disorders, and 
hepatobiliary disorders, showed higher incidences with CBZ. 
OXC has been proven to have anti-epileptic efficacy compa-
rable with CBZ8,9 and also has FDA approved indications for 
children. Based on this limited study, we recommend OXC as 
a first-line prescription of anti-epileptic drugs. Given the signifi-
cant number of ADR reports at daily doses below the recom-
Fig. 2. Incidence of ADRs to CBZ (A) and OXC (B) according to initial daily dose. ADR, adverse drug reaction; CBZ, carbamazepine; IR, immediate-release; 
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Fig. 1. The ratio of clinical features of ADRs to CBZ (A) and OXC (B). SCARs, severe cutaneous adverse reactions; ADR, adverse drug reaction; CBZ, car-
bamazepine; OXC, oxcarbazepine.
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mendation, initial doses of CBZ and OXC should be set even 
lower. Even in cases of severe ADRs, fast and proper manage-
ment by clinicians can prevent serious outcomes. 
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